Hypertension is a conditional factor for the development of cardiac hypertrophy in type 2 diabetic mice

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Van Bilsen, Marc ^a   Daniels, Anneleen ^a   Brouwers, Olaf ^a   Janssen, Ben J A ^a   Derks, Wouter J A ^a   Brouns, Agnieszka E ^a   Munts, Chantal ^a   Schalkwijk, Casper G ^a   Van Der Vusse, Ger J ^a   Van Nieuwenhoven, Frans A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; BIOLOGICAL MARKER; DOBUTAMINE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD PRESSURE; BODY WEIGHT; CARDITIS; CELL SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOBUTAMINE STRESS TEST; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; EXERCISE TEST; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERTENSION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION;

AMP-ACTIVATED PROTEIN KINASES; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CELL SIZE; DIABETES MELLITUS, TYPE 2; DOBUTAMINE; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MYOCARDIUM; MYOCYTES, CARDIAC; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84897445541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085078     Document Type: Article

References (39)

1. Howard BV, Rodriguez BL, Bennett PH, Harris MI, Hamman R, et al. (2002) Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology. Circulation 105: e132-137.
2. Kaplan NM, Opie LH (2006) Controversies in hypertension. Lancet 367: 168-176. (Pubitemid 43077131)
3. Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115: 3213-3223. (Pubitemid 47012236)
4. Fang ZY, Prins JB, Marwick TH (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25: 543-567. (Pubitemid 39096070)
5. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, et al. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30: 595-602.
6. Daniels A, Linz D, van Bilsen M, Rutten H, Sadowski T, et al. (2012) Long-term severe diabetes only leads to mild cardiac diastolic dysfunction in Zucker diabetic fatty rats. Eur J Heart Fail 14: 193-201.
7. Daniels A, van Bilsen M, Janssen BJ, Brouns AE, Cleutjens JP, et al. (2010) Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling. Acta Physiol (Oxf) 200: 11-22.
8. Ares-Carrasco S, Picatoste B, Benito-Martin A, Zubiri I, Sanz AB, et al. (2009) Myocardial fibrosis and apoptosis, but not inflammation, are present in longterm experimental diabetes. Am J Physiol Heart Circ Physiol 297: H2109-2119.
9. Falcao-Pires I, Palladini G, Goncalves N, van der Velden J, Moreira-Goncalves D, et al. (2011) Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload. Bas Res Cardiol 106: 801-814.
10. Fein FS, Zola BE, Malhotra A, Cho S, Factor SM, et al. (1990) Hypertensive-diabetic cardiomyopathy in rats. Am J Physiol 258: H793-805. (Pubitemid 20103213)
11. Kelly DJ, Zhang Y, Connelly K, Cox AJ, Martin J, et al. (2007) Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 293: H2860-2869. (Pubitemid 350106509)
12. Daugherty A, Rateri D, Hong L, Balakrishnan A (2009) Measuring blood pressure in mice using volume pressure recording, a tail-cuff method. J Vis Exp 1291 [pii] 10.3791/1291.
13. Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, et al. (2011) Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 286: 1374-1380.
14. Hanssen NM, Engelen L, Ferreira I, Scheijen JL, Huijberts MS, et al. (2013) Plasma Levels of Advanced Glycation Endproducts N{epsilon}- (carboxymethyl) lysine, N{epsilon}-(carboxyethyl)lysine, and Pentosidine Are not Independently Associated With Cardiovascular Disease in Individuals With or Without Type 2 Diabetes: The Hoorn and CODAM Studies. J Clin Endocrinol Metab 98: E1369-1373.
15. Nguyen DV, Shaw LC, Grant MB (2012) Inflammation in the pathogenesis of microvascular complications in diabetes. Frontiers in endocrinology 3: 170.
16. Romeo GR, Lee J, Shoelson SE (2012) Metabolic syndrome, insulin resistance, and roles of inflammation-mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 32: 1771-1776.
17. Bodiga VL, Eda SR, Bodiga S (2013) Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart failure reviews 10.1007/s10741-013-9374-y.
18. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, et al. (2006) Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 55: 466-473. (Pubitemid 43343277)
19. Yue P, Arai T, Terashima M, Sheikh AY, Cao F, et al. (2007) Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse. Am J Physiol Heart Circ Physiol 292: H2106-2118. (Pubitemid 47084589)
20. Reyes M, Steinhelper ME, Alvarez JA, Escobedo D, Pearce J, et al. (2006) Impact of physiological variables and genetic background on myocardial frequency-resistivity relations in the intact beating murine heart. Am J Physiol Heart Circ Physiol 291: H1659-1669. (Pubitemid 44497670)
21. Van den Bergh A, Flameng W, Herijgers P (2006) Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. Eur J Heart Fail 8: 777-783. (Pubitemid 44781425)
22. Alvarez JA, Reyes M, Escobedo D, Freeman GL, Steinhelper ME, et al. (2004) Enhanced left ventricular systolic function early in type 2 diabetic mice: clinical implications. Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 1: 89-94.
23. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA (2009) Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf) 195: 321-338.
24. Smeets PJ, Teunissen BE, Planavila A, de Vogel-van den Bosch H, Willemsen PH, et al. (2008) Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta. J Biol Chem 283: 29109-29118.
25. Bottero V, Imbert V, Frelin C, Formento JL, Peyron JF (2003) Monitoring NF-kappa B transactivation potential via real-time PCR quantification of I kappa Balpha gene expression. Mol Diagnos 7: 187-194. (Pubitemid 38533787)
26. Willemsen S, Hartog JW, van Veldhuisen DJ, van der Meer P, Roze JF, et al. (2012) The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am Heart J 164: 742-749 e743.
27. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR (2004) Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 279: 32771-32779. (Pubitemid 39014736)
28. Zhang P, Hu X, Xu X, Fassett J, Zhu G, et al. (2008) AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52: 918-924.
29. Hermida N, Markl A, Hamelet J, Van Assche T, Vanderper A, et al. (2013) HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. Cardiovasc Res 99: 44-54.
30. Bagi Z, Erdei N, Toth A, Li W, Hintze TH, et al. (2005) Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol 25: 1610-1616. (Pubitemid 41098929)
31. Senador D, Kanakamedala K, Irigoyen MC, Morris M, Elased KM (2009) Cardiovascular and autonomic phenotype of db/db diabetic mice. Exp Physiol 94: 648-658.
32. Park CW, Kim HW, Lim JH, Yoo KD, Chung S, et al. (2009) Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice. Diabetes 58: 2666-2676.
33. Tikellis C, Pickering R, Tsorotes D, Du XJ, Kiriazis H, et al. (2012) Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. Clin Sci (Lond) 123: 519-529.
34. Gonzalez-Quesada C, Cavalera M, Biernacka A, Kong P, Lee DW, et al. (2013) Thrombospondin-1 Induction in the Diabetic Myocardium Stabilizes the Cardiac Matrix, While Promoting Vascular Rarefaction Through Angiopoie-tin-2 Upregulation. Circ Res 10.1161/CIRCRESAHA.113.302593.
35. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, et al. (2005) Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146: 5341-5349. (Pubitemid 41653047)
36. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM (2003) Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108: 754-759. (Pubitemid 36999263)
37. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121: 748-757.
38. Shah AM, Shin SH, Takeuchi M, Skali H, Desai AS, et al. (2012) Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail 14: 185-192.
39. Falcao-Pires I, Hamdani N, Borbely A, Gavina C, Schalkwijk CG, et al. (2011) Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 124: 1151-1159.